Table 1 Demographic and clinical characteristics at baseline
Infliximab I | Etanercept II | Level of significance | |||||
|---|---|---|---|---|---|---|---|
MTX A | Other DMARD B | Mono-therapy C | MTX A | Other DMARD B | Mono-therapy C | ||
Number | 501 | 116 | 104 | 179 | 68 | 193 | |
Age (years) | 55.0 (13.6) | 57.4 (12.0) | 61.0 (12.1) | 53.4 (12.9) | 54.0 (12.4) | 57.7 (13.0) | IC vs. IIC, p = 0.040 IIA vs. IIC, p = 0.003 IA vs. IC, p < 0.001 IB vs. IC, p = 0.027 |
Female | 74% | 75% | 78% | 78% | 84% | 84% | |
Disease duration (months) | 133.5 (113.8) | 165.4 (118.5) | 192.9 (132.4) | 132.8 (107.3) | 180.1 (115.1) | 185.3 (121.4) | IIA vs. IIC, p < 0.001 IIA vs. IIB, p < 0.001 IA vs. IB, p = 0.002 IA vs. IC, p < 0.001 |
HAQ score | 1.34 (0.62) | 1.57 (0.58) | 1.69 (0.58) | 1.30 (0.61) | 1.61 (0.58) | 1.60 (0.65) | IIA vs. IIB, p < 0.001 IIA vs. IIC, p < 0.001 IA vs. IB, p < 0.001 IA vs. IC, p < 0.001 |
DAS28 | 5.5 (1.2) | 5.8 (1.1) | 5.7 (1.2) | 5.5 (1.0) | 5.8 (1.2) | 5.9 (1.1) | IIA vs. IIB, p = 0.026 IIA vs. IIC, p < 0.001 IA vs. IB, p = 0.013 |
Number of previous DMARDs | 3.1 (1.7) | 4.2 (2.2) | 4.2 (1.9) | 3.1 (1.1) | 4.2 (1.8) | 4.5 (2.1) | IIA vs. IIB, p < 0.001 IIA vs. IIC, p < 0.001 IA vs. IB, p < 0.001 IA vs. IC, p < 0.001 |
VASglobal (mm) | 60 (22) | 70 (18) | 67 (22) | 60 (22) | 71 (17) | 66 (21) | IIA vs. IIB, p = 0.001 IIA vs. IIC, p = 0.017 IA vs. IB, p < 0.001 IA vs. IC, p = 0.004 |
VASpain (mm) | 60 (23) | 70 (17) | 64 (24) | 60 (22) | 66 (19) | 65 (22) | IIA vs. IIC, p = 0.020 IA vs. IB, p < 0.001 |
EVALglobal (mm) | 57 (23) | 57 (22) | 58 (23) | 56 (24) | 56 (21) | 60 (24) | IIA vs. IIC, p = 0.015 |
MTX dosage (mg/week) | 14.3 (6.0) | - | - | 16.1 (5.0) | - | - | IA vs. IIA, p < 0.001 |
CRP (mg/litre) | 33.1 (34.0) | 39.5 (38.7) | 39.1 (36.6) | 32.1 (34.5) | 38.4 (30.0) | 41.6 (38.0) | IIA vs. IIB, p = 0.029 IIA vs. IIC, p = 0.008 |
ESR (mm/hour) | 35.0 (24.1) | 42.1 (26.8) | 44.0 (28.2) | 34.2 (23.1) | 41.9 (25.0) | 44.4 (27.1) | |